Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the safety, tolerability, and immunogenicity of Recombinant Botulinum Vaccine A/B in healthy adults and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Botulism

Drugs mentioned

• Recombinant Botulinum Vaccine A/B

Snippet

Sponsor: DynPort Vaccine Company LLC, A GDIT Company | Conditions: RECOMBINANT BOTULINUM VACCINE A/B | Phase 1 | Status: COMPLETED